Which late-stage drug programs will reach approval — and when? Pipette Dreams turns trial evidence, FDA catalysts, and standard-of-care benchmarks into explainable scores for clinical strength, regulatory confidence, and approval potential, with a model that sharpens as outcomes resolve.
7 days of full access, no payment required. After the trial, keep limited free access or upgrade to Pro anytime. Not investment advice.
Ranked by Approval Potential
Built from published trial results — endpoints, effect sizes, safety profile, and study design quality.
FDA designations, meeting outcomes, and the catalyst calendar ahead — with confirmed vs. estimated dates.
An explainable estimate of regulatory success, plus the commercial opportunity and valuation if it pays off.
Clinical evidence, regulatory timelines, standard-of-care benchmarks, and commercial modeling — connected so you can evaluate a program end to end.
Every program scored on clinical strength, regulatory confidence, and approval potential — each traceable to the underlying data, not a black-box rating.
PDUFA dates, advisory committees, pivotal data readouts, and BLA/NDA submissions — with confirmed vs. estimated dates and source verification.
Compare experimental therapies against current standard of care by efficacy, safety, treatment burden, and mechanism — is the drug actually better?
Eligible patient populations, estimated treatment price, and bear/base/bull revenue scenarios translate a clinical win into a commercial opportunity and potential valuation.
A conversational assistant to interrogate program data, ask follow-up questions, and surface the evidence behind each conclusion.
Track the programs that matter to you and see upcoming catalysts in one consolidated view.
Every time a catalyst resolves, the platform compares its prediction to the actual result — learns the bias — and corrects the next one. The gap closes a little more each cycle.
Each time a catalyst resolves, the model compares its predicted upside to the actual stock move — learns the bias — and corrects the next prediction. The gap shrinks every cycle.
Research, not advice. All scores and analyses on Pipette Dreams are AI-generated, impersonal estimates — not ratings or recommendations. Nothing here is an offer to buy, sell, or hold any security. Always do your own due diligence.
Create an account for seven days of full access, then continue with limited free access or upgrade to Pro.